DGX
Quest Diagnostics
$193.58
▼ 0.7%Updated Today 7:15 PM ET
▲ Up 8.5% over the last 12 months
Market Cap
$21.59B
P/E
21x
Forward P/E (est.)
18.28x
ROE
14.1%
Revenue Growth
11.0%
EPS Growth
14.9%
Profit Margin
9.1%
FCF Yield
5.4%
Debt / Equity
0.82x
ROIC
9.0%
Interest Coverage
9.55x
Current Ratio
1.18x
Dividend Yield
1.7%
Implied Growth (rev. DCF)
2.5%
Rating Score
57/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DGX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DGX trades near $193.58, around its 50-day average ($194.94) and 200-day average ($189.50). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 53 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. DGX's is $4.65 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month DGX found buyers near $188.88 (support) and sellers near $207.50 (resistance); its 52-week range is $164.65–$213.50. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Quest Diagnostics (DGX) is a large-cap company in the Health Care Services industry, part of the Health Care sector of the S&P 500, with a market value around $21.59B.
In its latest reported year it generated about $11.04B in revenue and $992.00M in net profit.
Our model rates DGX Neutral (57/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
0.6%
Revenue moved from $10.79B in 2021 to $11.04B in 2025, a 0.6% compound annual growth rate. The most recent year grew a steady 11.0% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
33.3%
Operating Margin
14.1%
Net Margin
9.0%
ROE
14.1%
Quest Diagnostics keeps about 9.1% of each sales dollar as net profit, with a 33.3% gross margin and 14.1% operating margin. Return on equity is 14.1% and return on invested capital about 9.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$5.67B
Net Debt
$5.28B
Net Debt / EBITDA
3.39x
Debt / Equity
0.82x
Leverage: debt-to-equity is 0.8x, and operating profit covers interest about 9.6x, with a current ratio of 1.2x. That is a moderate, manageable debt load for most businesses. It carries roughly $5.67B of total debt against $393.00M of cash.
Operating CF
$1.89B
Free Cash Flow
$1.36B
FCF Margin
12.3%
In the latest year Quest Diagnostics produced about $1.89B of operating cash flow and $1.36B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.4% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
21x
P/S
2.01x
P/B
2.61x
EV / EBITDA
12.95x
DGX trades at 21.0x trailing earnings (about 18.3x on estimated forward earnings), 2.0x sales, and 2.6x book value. Reverse-engineering today's price implies the market expects roughly 2.5% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How DGX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), DGX ranks #23 of 59 by our overall rating. It trades at a discount versus the sector on earnings (21x P/E vs. 25.4x median) with a lower return on equity (14.1% vs. 14.9%) and faster revenue growth (11.0% vs. 7.9%).
P/E vs sector
21x
median 25.4x
ROE vs sector
14.1%
median 14.9%
Growth vs sector
11.0%
median 7.9%
Sector rank
#23
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$196.53 – $317.48
vs. $193.58 today · expected CAGR 0% – 10%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $12.25B | $13.60B | $15.09B | $16.75B | $18.59B |
| Net income | $1.10B | $1.22B | $1.36B | $1.51B | $1.67B |
| EPS | $9.96 | $11.05 | $12.27 | $13.62 | $15.12 |
| Share price (low) | $129.46 | $143.70 | $159.51 | $177.06 | $196.53 |
| Share price (high) | $209.13 | $232.14 | $257.67 | $286.02 | $317.48 |
| CAGR (low–high) | -33% / 8% | -14% / 10% | -6% / 10% | -2% / 10% | 0% / 10% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for DGX:
- Revenue is growing 11.0% a year, a sign of real demand.
- Healthy free-cash-flow yield (~5.4%) funds buybacks and dividends.
The case against DGX:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Quest Diagnostics is a large-cap health care business still growing nicely, with modest profitability, and a heavier debt load to watch. It trades at 21.0x earnings, which our model scores Neutral (57/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.